Categories AlphaGraphs, Earnings, Health Care
ANGO Earnings: AngioDynamics reports loss for Q3; revenue up 9%
AngioDynamics Inc. (NASDAQ: ANGO) on Thursday reported a wider loss for the third quarter when the medical device maker’s revenues increased by 9%. The company also provided guidance for fiscal 2023.
AngioDynamics reported an adjusted net loss of $0.03 per share for the third quarter, compared to earnings of $0.03 per share in the year-ago period. On an unadjusted basis, it was a net loss of $9.49 million or $0.24 per share, compared to a loss of $4.96 million or $0.13 per share in the third quarter of 2022.
Meanwhile, third-quarter revenues increased 9% year-over-year to $80.7 million. The management expects full-year revenues to be in the range of $338 million to $342 million.
“We continued to make solid progress during the quarter executing on our strategic plan. Auryon, AlphaVac, NanoKnife, and our Med Device portfolio were bright spots during the third quarter, and while we experienced continued softness in AngioVac, we have taken steps to address the performance, and it remains an important driver for AngioDynamics’ growth,” said Jim Clemmer, CEO of AngioDynamics.
Most Popular
Broadcom (AVGO) thrives on growing AI business. Is the stock a buy?
Broadcom, Inc. (NASDAQ: AVGO), a leading provider of semiconductor solutions for wired and wireless communications, recently impressed the market with upbeat financial outlook highlighting strong prospects for its AI business
After a weak first half, will NIKE (NKE) hit the recovery path this year?
After a prolonged slowdown, NIKE, Inc. (NYSE: NKE) is working on a turnaround plan to regain the brand’s strength. In recent years, the sneaker giant’s overall performance has not been
Lennar (LEN): Even the best-laid plans can go wrong
Shares of Lennar Corporation (NYSE: LEN) stayed green on Monday. The stock has dropped 25% over the past three months. The homebuilder delivered underwhelming results for the fourth quarter of
